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The aim of this study was to analyse the correlation 
between a new multiplex qPCR assay and a reference 
qPCR assay for assessment of the human papillomavirus 
(HPV16) load and the viral genome status. The study was 
performed on 100 HPV16 positive samples containing 
premalignant lesions and carcinomas. HPV16 E2 and E6 
gene loads were assessed by two PCR methods. The load 
of E2 and E6 was normalized to the cell number by qPCR 
targeting the RNase P open reading frame. The physi-
cal state of the viral genome was determined as a ratio 
of E2/E6 copies number per cell. Among 100 samples 
analysed, there were no statistically significant differ-
ences in the E2 and E6 viral load evaluated by multiplex 
qPCR and qPCR, the correlation coefficients were 0.98 
and 0.97, respectively. There were 19% of samples with 
the integrated, 73% with mixed and 8% with episomal 
state of viral genome detected by multiplex qPCR and 
17%, 79%, 4%, respectively, found by qPCR. Prevalence 
of integrated and episomal forms estimated by multiplex 
qPCR was higher than the one obtained by qPCR (Chi2, 
p < 0.0001), but in samples with premalignant and malig-
nant diagnoses no significant differences were demon-
strated regardless of the methods used. Sensitivity and 
specificity of multiplex qPCR were 93.7% and 100% as 
compared with qPCR, the positive predictive value was 
100%. In summary, the multiplex qPCR assay in respect 
of HPV16 load and the frequency of viral genome status 
was shown to be a sensitive and specific reference meth-
od. Simultaneous estimation of E2 and E6 genes in one 
reaction tube reduces the cost of testing.
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INTRODUCTION
Human papillomaviruses (HPVs) classified in the Pap-
illomaviridae family infect skin or mucosal epithelial cells 
(de Villiers et al., 2013). Among more than 100 types of 
HPV, at least 13, are known as high risk type and can 
cause cancer of the cervix, other anogenital organs, or 
head and neck. Other HPV types with low oncogenic 
potential cause non-malignant lesions, such as anogenital 
warts. In most sexually active women, HPV infections 
are asymptomatic and transient and only a minority of 
them will develop persistent infection that could eventu-
ally cause precursor lesions such as low- or high-grade 
squamous intraepithelial lesions (LSIL, HSIL) (zur Haus-
en, 2002, Munoz et al., 2003).
Several factors contribute to HPV persistence and de-
velopment of cervical cancer: immunosuppression due 
to infection with HIV or other microorganisms, multi-
parity, early initiation of sexual life, long-term hormonal 
contraceptive use, smoking and infections with other 
sexually transmitted diseases (Faridi et al. 2011). How-
ever, additional risk markers are needed which can be 
host- or virus-related factors such as HPV type, integra-
tion stage or viral load. Persistence of high risk type of 
human papillomaviruses, particularly HPV16, leads to 
integration of the virus into the host genome and then 
to disease progression. The genome integration of HPV 
usually disrupts or deletes E2, and rarely E1 open read-
ing frames, which results in the loss of expression of the 
corresponding gene products. Disruption of these genes 
also leads to over-expression of the E6 and E7 onco-
proteins, since the E2 gene product can repress activities 
from the HPV promoter (Schmidt et al., 2005; Howley 
et al., 2013). This process leads to increased expression 
of E6 and E7 viral oncoproteins which target the p53 
and pRb tumor suppressor proteins, respectively, result-
ing in loss of cell-cycle control and downregulation of 
their anti-tumor functions (Dyson et al., 1989, Scheffner 
et al., 1990). So far, different methods have been used 
to determine the HPV16 physical status, such as two-
dimensional gel electrophoresis, Southern blotting, in situ 
hybridisation, multiple displacement amplification as an 
isothermal whole genome amplification technique and 
various types of PCR (Gallo et al., 2003; Hudelist et al., 
2004; Evans et al., 2007).  Several methods have been 
introduced based on PCR: PCR or multiplex PCR assay 
of E2 region integrity (Das et al., 1992; Szostek et al., 
2008), quantitative real-time PCR (qPCR) assay of the 
ratio of E2 to E6/E7 region amplicons (Peitsaro et al., 
2002; Mazumder et al., 2011; Ruutu et al., 2008; Biesaga 
et al., 2012), amplification of papillomavirus oncogene 
transcripts test (APOT) (Vinokurova et al., 2008). Test 
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results obtained by different methods have suggested 
that the HPV16 integration status might be a marker for 
cervical precancerous lesion progression. 
The aim of present study was to apply a new mul-
tiplex real-time PCR-based assay (multiplex qPCR) to 
assess the HPV16 physical status and load in low- and 
high-grade squamous intraepithelial lesions of the cervix, 
and cervical cancer. The results obtained by this new 
method were compared with reference method - qPCR, 
in which E2 and E6 gene loads are assessed individually. 
MATERIALS AND METHODS
Materials. The study was performed on a hundred 
HPV16 positive samples (66 cervical smears and 34 
cervical cancer biopsies) confirmed by the INNO-LiPA 
HPV genotyping assay (Innogenetics). Clinical materi-
als were obtained from women at ages of 20–77 years 
(mean 45 ± 15) with different diagnoses: low-grade squa-
mous intraepithelial lesions – LSIL (n = 38), high-grade 
squamous intraepithelial lesions – HSIL (n = 6) and cer-
vical carcinoma (n = 56, FIGO stage I-III). All cancer 
patients were treated at the Maria Skłodowska-Curie Me-
morial Cancer Center and Institute of Oncology, Cracow 
Branch, Poland. The study has been approved by the 
Ethics Committee of the Jagiellonian University.
All samples were taken after cytology examination but 
before treatment. Cervical smears were collected into 
a saline solution and stored frozen at –70°C until pro-
cessed. 
Cervical cancer biopsies were reviewed by a patholo-
gist in order to confirm diagnoses. For DNA isolation, 
the paraffin-embedded tissue samples were cut into five 
to eight 5-µm thick sections. 
DNA isolation. DNA extraction was carried out 
from cervical smears using Genomic DNA Prep Plus 
kit (A&A Biotechnology, Poland), whereas isolation of 
DNA from paraffin-embedded samples was performed 
using EX-WAXTM DNA Extraction Kit (Millipore-
Chemicon International, USA) according to the manu-
facturer’s instructions.  
Quantitative real-time PCR. Amplification was per-
formed using the ABI Prism 7500 Fast Real-Time PCR 
Systems for HPV16 E6 and E2 genes according to Si 
et al. (2005) using primers, probes and qPCR conditions 
described by Biesaga et al. (2012). 
The reference method (qPCR) and multiplex qPCR 
were performed simultaneously. Quantity of E2 and E6 
genes was determined separately in qPCR and in one 
tube in multiplex qPCR.
To generate standard curves for E6 and E2 of 
HPV16, the serially diluted DNA plasmid (pBR322-
HPV-16, ATCC 45113) containing 5 × 104, 5 × 105, 
5 × 106, 5 × 107, 5 × 108, 5 × 109  HPV-16 DNA genome 
copy numbers was used in three replicates for each di-
lution point. Experiments were repeated five times to 
determine the linearity of amplification. Standard curves 
were drawn using serial dilutions of known target gene 
copy numbers vs. corresponding Ct values and fitted by 
the least-square fit method. SiHa cells were used as posi-
tive control of HPV16 integration to host DNA. For E2 
and E6 gene quantification, the absolute copy number in 
the unknown samples was calculated by plotting the Ct 
values against the logarithm of the standard curve.
Each cervical sample was subjected to qPCR for 
quantification of human RNase P gene. The standard 
curve used for the human RNase P gene quantification 
was made according to the manufacturer’s instructions 
with four decimal serial dilutions of calibrated human 
genomic DNA, containing 7500, 750, 75, 7.5 RNase P 
gene copies (TaqMan RNase P Detection Reagents Kit, 
Applied Biosystems).
Viral load detection. The load of E2 and E6 was 
determined using a copy number normalized per cell. 
The number of cells was assessed by qPCR targeting the 
RNase P open reading frame.
Physical state determination. The viral physical 
state was estimated as a ratio of  E2 to E6 copy num-
bers per cell.
To assess the validity of the method, E2/E6 ratios 
were determined for mixes containing known E2 and 
E6 copy numbers. For this purpose, we prepared a se-
ries made with mixes of  pBR322–HPV16 plasmids (as 
episomal forms) and DNA of SiHa cells (as integrated 
forms; one to two copies/cell) with ratios varying from 
0 to 1. All these combinations were analysed in dupli-
cate, and five times independently using the multiplex 
qPCR  method and the reference method — qPCR. 
The E2/E6 ratios were calculated to determine the pure 
episomal (E2/E6 ≥ 1.0), the  mixed (both integrated and 
episomal forms present in a single sample) (0.99 > E2/
E6 > 0.05) and the integrated (E2/E6 ≤ 0.05) forms. Af-
ter this validation step, the DNA from the 44 HPV16 
positive premalignant samples and 56 HPV16 positive 
cervical carcinomas were examined in triplicate by multi-
plex qPCR and the reference qPCR methods.
Statistical analysis. The statistical analysis was done 
using the STATA 10.0 software package. Descriptive sta-
tistics were used to determine mean and median values 
of continuous variables and standard errors of means. 
Correlations between Ct levels were analysed by correla-
tion matrix in which R coefficients and p values were 
calculated. Additionally, statistical significance of the dif-
ferences between qPCR and multiplex qPCR was estab-
lished by Student’s t-test and non-parametric U Mann 
-Whitney and Kruskal-Wallis tests. Dichotomous vari-
ables were analysed using the chi-square test. A p-value 
less than 0.05 was considered significant. 
RESULTS
In a first stage of our study standard curves for E2 
and E6 genes of  HPV16 were established. Results es-
timated in qPCR and  multiplex qPCR plotted by least-
square fit method were shown in Fig. 1. The sensitivity 
of both PCR methods was 102 viral copies. 
Among 100 analysed samples, there were no statisti-
cally significant differences in the E2 and E6 viral load 
obtained in the two tested methods (U Mann-Whitney 
test, p = 0.41 and  p=0.34, respectively). The correla-
tion coefficients were 0.98 for E2 and 0.97 for E6 gene 
(Fig. 2). 
Physical status of HPV16 genome estimated by mul-
tiplex qPCR revealed 19% of samples with integrated, 
73% with mixed and 8% with episomal state of HPV16 
genome while in qPCR the percentages were 17%, 79% 
and 4%, respectively. The multiplex qPCR method 
showed a higher, statistically significant incidence of in-
tegrated and episomal forms of viral genome than this 
obtained by qPCR (Chi2, p < 0.0001). These results are 
shown in Fig. 3. Viral load of HPV- (targeting HPV16 
E6 open reading frame) for each physical stage estimated 
in both methods is presented in Fig. 4. The prevalence 
of integrated, episomal and mixed forms of HPV16 ge-
nome in samples with premalignant and cervical cancer 
diagnoses did not significantly differ in both of the stud-
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ied methods (Pearson’s Chi2 test, p = 0.2) (Fig. 5). The 
sensitivity and specificity of multiplex qPCR were 93.7% 
and 100%  as compared to qPCR, positive predictive 
value was 100%.  
DISCUSSION
It is well-known that a high-risk HPV infection may 
progress to cervical cancer within several years, but only 
about ten percent of these infections persist in host cells 
and evolve into premalignant lesions (Moscicki et al., 
2006). Therefore, it is important to identify the biomark-
ers that contribute to the development of cervical cancer 
and then determine women with a real risk of cancer. 
The HPV16 DNA integration into host genome has 
been regarded to be a key step in the progression to-
wards invasive cancer (zur Hausen, 2009). However, the 
frequency of viral integration into the host genome in 
premalignant and malignant lesions is under discussion 
(Nagao et al., 2002; Peitsaro et al., 2002; Hudelist et al., 
Figure 1. Standard curves for HPV-16 E2 and E6 sequences tested by multiplex qPCR (A, C) and qPCR (B, D).
Figure 2. Correlation between results obtained by multiplex qPCR and qPCR for the HPV-16 E2 and E6 sequences in 100 samples 
analyzed.
A B
C D
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2004; Kumala et al., 2006; Arias-Pulido et al., 2006; Shuk-
la et al., 2014; Ribeiro et al., 2014). It has been proposed 
that integration can either be an early event associated 
with progression from LSIL to HSIL, or a later event 
that accompanies progression from HSIL to cervical 
cancer (Groves & Coleman, 2015). 
The main methods for detection of  HPV integration 
are based on fluorescence in situ hybridization, PCR, and 
qPCR (Abreu et al., 2012). In the present study, the ratio 
between the levels of viral E2 and E6 loads was calcu-
lated by a new multiplex qPCR assay and qPCR as the 
reference method.  
In our study, criteria for assessing the HPV-16 physi-
cal status were estimated based on artificial combination 
of DNA isolated from SiHa cells and pBR322-HPV-16 
plasmid. The established values for each status (E2/
E6 ≥ 1.0 for pure episomal,  ≤ 0.05 for  integrated and 
between 0.05–0.99 for mixed (integrated and episomal 
forms) were similar to those of Mazumder Indra et al. 
(2011)  and Dutta et al. (2015), who used Power SYBR 
Green qPCR for HPV16 physical state assessment. Oth-
er authors have used a slightly different criteria and the 
differences were mostly related to the cut-off for the 
episomal form (Peitsaro et al., 2002; Arias-Paulido et al., 
2006; Cricca et al. 2007; Saunier et al., 2008;). The ratio 
of E2/E6 ≥ 1.0 for the pure episomal form was used 
the most frequently (Kulmala et al., 2006; Mazumder In-
dra et al., 2011; Biesaga et al., 2012; Shukla et al., 2014). 
Canadas et al. (2010a) applied a multiplex qPCR based 
on validation of simultaneous amplification of E2 and 
E6 HPV16 genes in SiHa cells using as a control for 
HPV16 integration and anal cell samples from asymp-
tomatic patients with transient HPV16 infection as an 
episomal control. In subsequent studies, this method was 
used for the detection of HPV16 physical status in cer-
vical exfoliated cells obtained from women with normal 
and atypical cytology and cervical cancer (Canadas et al., 
2010b; Ribeiro et al., 2014). Based on these studies and 
material with different severity of the lesions, these au-
thors confirmed that the integration of HPV16 may be 
a good biomarker for the evolution of CIN into cervical 
carcinoma but further research is required to corroborate 
it. Other authors also drew attention to the direct cor-
Figure 3. The physical status of HPV-16 genome estimated us-
ing multiplex qPCR and qPCR.
Figure 4. Comparison of HPV-16 viral load in different physical 
statuses of genome. 
Differences are statistically significant (p < 0.001, Kruskal-Wallis 
test).
Figure 5. Comparison of HPV-16 physical status in premalignant and cervical cancer samples estimated by multiplex qPCR and qPCR.
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relation between the frequency of integration of HPV16, 
which increased with the severity of lesions in the cer-
vix (Guo et al., 2007; Saunier et al., 2008; Shukla et al., 
2014).  In our study, women with invasive cervical can-
cer accounted for 56% of the studied population and 
the HPV16 integration in this group was present only 
in 29% and 32% of cases, depending on the method ap-
plied (multiplex qPCR and qPCR, respectively). In the 
subgroup of women with a premalignant lesion, the vi-
ral integration was confirmed only in one case. In most 
women with cervical cancer, the mixed form of the ge-
nome was detected (59% and 68% by multiplex qPCR 
and qPCR, respectively). Such a high frequency of the 
mixed form in cancer patients may result from the fact 
that excess episomal copies might mask the integrat-
ed form of HPV16 (Ruutu, 2008). On the other hand, 
it may be a consequence of differences in FIGO stage 
among studied cancers. Arias-Pulido et al. (2006) showed 
significant differences in the occurrence of the mixed 
form of HPV16 regarding carcinoma in situ and invasive 
cervical cancer, in  29.4% and 47.5%, respectively. The 
high rate of the mixed form of HPV-16 in our samples 
may also be explained by the presence of a mutation in 
the E2 sequence or the viral DNA disruption outside 
the E2 region (Arias-Pulido et al., 2006; Jiang et al., 2009; 
Li et al., 2013). 
Mixed form of the viral genome was detected as the 
most common in premalignant lesions (41%) and cervi-
cal cancer (68%). This result is similar to the one dem-
onstrated by other authors using qPCR (Kulmala et al., 
2006; Guo et al., 2007; Saunier et al., 2008). 
In our cases, the frequency of integrated form corre-
lated in a statistically significant way with HPV16 load. 
Viral load increases with severity of lesions. To our 
knowledge, there are no published studies in which the 
results achieved by qPCR and multiplex qPCR are com-
pared. Only in the discussion section of the paper by 
Peisaro et al. (2002), the authors’ preliminary experiments 
with multiplexing qPCR were mentioned but as quoted 
“the data obtained were less reliable than those obtained 
when the reaction was ran in two separate tubes”. In 
conclusion, our results obtained by multiplex qPCR in 
respect of HPV16 load and the frequency of viral ge-
nome status are similar to those obtained by the refer-
ence method. Since multiplex qPCR  allows for simulta-
neous evaluation of the two HPV genes in one reaction 
tube and thereby for reduction of the cost, we recom-
mend this test for cervical cancer screening. Presented 
results suggest that HPV16 viral load and physical status 
of viral genome have predictive potential as biomarkers 
of carcinogenesis, although further studies are needed to 
confirm this thesis.
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